| Size | Price | |
|---|---|---|
| 5mg | ||
| 50mg | ||
| 500mg |
| ln Vivo |
In a dose-dependent manner, α-CGRP (mouse, rat) (<0.1 mL; supra-aortic injection, single dose) raises heart rate [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat [1]
Doses: <0.1 mL Route of Administration: Supraaortic injection, single dose Experimental Results: Heart rate increased in a dose-dependent manner. |
| References |
[1]. Holman JJ, et al. Human alpha- and beta-CGRP and rat alpha-CGRP are coronary vasodilators in the rat. Peptides. 1986 Mar-Apr;7(2):231-5.
[2]. Arulmani U, et al. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol. 2004 Jun;94(6):291-7. [3]. Gorzi A, et al. Muscle gene expression of CGRP-α, CGRP receptor, nAchR-β, and GDNF in response to different endurance training protocols of Wistar rats. Mol Biol Rep. 2020 Jul;47(7):5305-5314. |
| Molecular Formula |
C162H262N50O52S2
|
|---|---|
| Molecular Weight |
3806.24751329422
|
| CAS # |
83651-90-5
|
| SMILES |
S1C[C@@H](C(N[C@H](C(N[C@@H]([C@@H](C)O)C(N[C@@H](CC2=CNC=N2)C(N[C@H](C(N[C@H](C(N[C@@H](C)C(NCC(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CO)C(NCC(NCC(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(=O)O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2C=CC=CC=2)C(N[C@@H](C(C)C)C(N2CCC[C@H]2C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC2C=CC=CC=2)=O)C)=O)CCC(=O)O)=O)CO)=O)=O)C(C)C)=O)CC(N)=O)=O)[C@@H](C)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCCNC(=N)N)=O)=O)CC(C)C)=O)CC(C)C)=O)=O)=O)CC(C)C)=O)CCCNC(=N)N)=O)=O)=O)C(C)C)=O)NC([C@H]([C@@H](C)O)NC([C@H](C)NC([C@H]([C@@H](C)O)NC([C@H](CC(N)=O)NC([C@H](CS1)NC([C@H](CO)N)=O)=O)=O)=O)=O)=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2627 mL | 1.3136 mL | 2.6273 mL | |
| 5 mM | 0.0525 mL | 0.2627 mL | 0.5255 mL | |
| 10 mM | 0.0263 mL | 0.1314 mL | 0.2627 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
